{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T10:04:17Z","timestamp":1760609057082},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T00:00:00Z","timestamp":1520380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the Anticancer Major Special Project of Tianjin","award":["12ZCDZSY18000"],"award-info":[{"award-number":["12ZCDZSY18000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12288-018-0937-x","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T16:23:07Z","timestamp":1520439787000},"page":"216-226","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"34","author":[{"given":"Fengjuan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"937_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V (2003) Molecular mechanisms of amyloidosis. N Engl J Med 349:583\u2013596","journal-title":"N Engl J Med"},{"key":"937_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11864-006-0015-8","volume":"7","author":"RL Comenzo","year":"2006","unstructured":"Comenzo RL (2006) Amyloidosis. Curr Treat Options Oncol 7:225\u2013236","journal-title":"Curr Treat Options Oncol"},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/JCO.1999.17.1.262","volume":"17","author":"MA Gertz","year":"1999","unstructured":"Gertz MA, Lacy MQ, Lust JA et al (1999) Prospective randomized trial of melphalan and prednisone versus vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of primary systemic amyloidosis. J Clin Oncol 17:262\u2013267","journal-title":"J Clin Oncol"},{"key":"937_CR4","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S0002-9343(97)89487-9","volume":"100","author":"M Skinner","year":"1996","unstructured":"Skinner M, Anderson J, Simms R et al (1996) Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100:290\u2013298","journal-title":"Am J Med"},{"key":"937_CR5","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352:2487\u20132498","journal-title":"N Engl J Med"},{"key":"937_CR6","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"MJ San","year":"2008","unstructured":"San MJ, Schlag R, Khuageva NK et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906\u2013917","journal-title":"N Engl J Med"},{"key":"937_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA et al (2010) Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol 28:1031\u20131037","journal-title":"J Clin Oncol"},{"key":"937_CR8","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1182\/blood-2009-02-203398","volume":"114","author":"DE Reece","year":"2009","unstructured":"Reece DE, Sanchorawala V, Hegenbart U et al (2009) Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood 114:1489\u20131497","journal-title":"Blood"},{"key":"937_CR9","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3324\/haematol.11325","volume":"92","author":"E Kastritis","year":"2007","unstructured":"Kastritis E, Anagnostopoulos A, Roussou M et al (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 92:1351\u20131358","journal-title":"Haematologica"},{"key":"937_CR10","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3324\/haematol.11627","volume":"93","author":"AD Wechalekar","year":"2008","unstructured":"Wechalekar AD, Lachmann HJ, Offer M, Hawkins PN, Gillmore JD (2008) Efficacy of bortezomib in systemic AL amyloidosis with relapsed\/refractory clonal disease. Haematologica 93:295\u2013298","journal-title":"Haematologica"},{"key":"937_CR11","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.3324\/haematol.12136","volume":"92","author":"R Sitia","year":"2007","unstructured":"Sitia R, Palladini G, Merlini G (2007) Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica 92:1302\u20131307","journal-title":"Haematologica"},{"key":"937_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2012.09.011","volume":"13","author":"A Chari","year":"2013","unstructured":"Chari A, Barley K, Jagannath S, Osman K (2013) Safety and efficacy of triplet regimens in newly diagnosed light chain amyloidosis. Clin Lymphoma Myeloma Leuk 13:55\u201361","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"937_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH et al (2005) Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol 79:319\u2013328","journal-title":"Am J Hematol"},{"key":"937_CR14","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"KF Schulz","year":"1995","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG (1995) Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273:408\u2013412","journal-title":"JAMA"},{"key":"937_CR15","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","volume":"124","author":"DE Reece","year":"2014","unstructured":"Reece DE, Hegenbart U, Sanchorawala V et al (2014) Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood 124:2498\u20132506","journal-title":"Blood"},{"key":"937_CR16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","volume":"118","author":"DE Reece","year":"2011","unstructured":"Reece DE, Hegenbart U, Sanchorawala V et al (2011) Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study. Blood 118:865\u2013873","journal-title":"Blood"},{"key":"937_CR17","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/qjmed\/hcr105","volume":"104","author":"SW Dubrey","year":"2011","unstructured":"Dubrey SW, Reece DE, Sanchorawala V et al (2011) Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM 104:957\u2013970","journal-title":"QJM"},{"key":"937_CR18","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1038\/leu.2014.218","volume":"28","author":"CP Venner","year":"2014","unstructured":"Venner CP, Gillmore JD, Sachchithanantham S et al (2014) A matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis. Leukemia 28:2304\u20132310","journal-title":"Leukemia"},{"key":"937_CR19","doi-asserted-by":"publisher","first-page":"E60","DOI":"10.1002\/ajh.23936","volume":"90","author":"E Kastritis","year":"2015","unstructured":"Kastritis E, Roussou M, Gavriatopoulou M et al (2015) Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies. Am J Hematol 90:E60\u2013E65","journal-title":"Am J Hematol"},{"key":"937_CR20","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1038\/leu.2014.227","volume":"28","author":"G Palladini","year":"2014","unstructured":"Palladini G, Milani P, Foli A et al (2014) Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients. Leukemia 28:2311\u20132316","journal-title":"Leukemia"},{"key":"937_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1741-7015-12-2","volume":"12","author":"X Huang","year":"2014","unstructured":"Huang X, Wang Q, Chen W et al (2014) Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial. BMC Med 12:2","journal-title":"BMC Med"},{"key":"937_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.clml.2014.02.003","volume":"14","author":"EC Scott","year":"2014","unstructured":"Scott EC, Heitner SB, Dibb W et al (2014) Induction bortezomib in AL amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study. Clin Lymphoma Myeloma Leukemia 14:424\u2013430","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"937_CR23","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.healun.2016.03.004","volume":"35","author":"I Sayago","year":"2016","unstructured":"Sayago I, Krsnik I, G\u00f3mez-Bueno M et al (2016) Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis. J Heart Lung Transplant 35:995\u20131002","journal-title":"J Heart Lung Transplant"},{"key":"937_CR24","first-page":"283","volume":"37","author":"Q Zhao","year":"2016","unstructured":"Zhao Q, Wang L, Song P et al (2016) Comparison analysis of outcomes in primary light chain amyloidosis patients treated by auto peripheral blood stem cell transplantation or bortezomib plus dexamethasone. Zhonghua Xue Ye Xue Za Zhi 37:283\u2013287","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"937_CR25","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1038\/bcj.2017.47","volume":"7","author":"E Kastritis","year":"2017","unstructured":"Kastritis E, Gavriatopoulou M, Roussou M et al (2017) Addition of cyclophosphamide and higher doses of dexamethasone do not improve outcomes of patients with AL amyloidosis treated with bortezomib. Blood Cancer J 7:e570","journal-title":"Blood Cancer J"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12288-018-0937-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-018-0937-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-018-0937-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T01:24:41Z","timestamp":1551921881000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12288-018-0937-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s12288-018-0937-x","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"assertion":[{"value":"26 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studides with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}